Embracing innovative, digital transformation has allowed biopharmaceutical companies to improve manufacturing processes and quality to better benefit their clients. Samsung Biologics has been taking innovative approaches to its business practices in delivering optimized efficiency and greater client satisfaction. Integrated systems, enhanced virtual user experience, and continued investments in digital transformation are just a few of the technology initiatives leveraged by Samsung Biologics to adapt flexibly in the new COVID-era.
 
Ensuring Secure Access
 
Samsung Biologics recently launched its Enterprise Quality Unified Information System (EQUIS), which integrated two separate systems—Electronic Document Management System (EDMS) and Electronic Quality Management System (EQMS)—into one. As a cloud-based platform, EQUIS allows qualified employees to manage quality records and documents in real-time on a single platform, ultimately improving cGMP record tracking, documentation, and assessment. The system gives external clients direct access to request, review, and approve documents and records related to their products on-demand.
 
As the first CDMO to implement this fully natively integrated system, Samsung Biologics is leading the industry one step further in advanced digitalization.
 
Minimizing Paper Footprint
 
As the biopharma industry continues to integrate more and more modern digital solutions into the manufacturing space, Samsung Biologics is also adapting quickly. Replacing paper binders with mobile tablet devices on the manufacturing floor and quality control labs allowed Samsung Biologics to streamline day-to-day tasks. With paper binders, it was difficult to locate, update, and track procedures, as well as to ensure that operators are working with the latest procedures.
 
Delivering the most up-to-date content directly to the manufacturing floor and quality control labs through an EQUIS-connected mobile application not only increased efficiency and reduced compliance risks, but also improved visibility across the company as the integrated solutions kept teams better aligned.
 
Building Virtual Connections
 
Videoconferencing, webinars, and virtual tours have allowed Samsung Biologics to communicate and serve clients while also keeping their safety in mind amid the COVID-19 pandemic. The Virtual Exhibition Hall and Live Virtual Tour solutions introduced new platforms where through high definition virtual connectivity, clients are able to view the company’s business services and have richer conversations with their experts. As most biopharma conferences have moved virtually, the company has also focused on still being present in those spaces through webinars and virtual networking forums.

Optimized for both mobile and desktop, the Virtual Exhibition Hall  provides an innovative, virtualized conference experience offering convenience for clients and industry professionals interested in learning more about the company and its CMO, CDO, and CRO services.
 
Live Virtual Tour (LVT) helps clients and regulatory auditors remotely assess facilities as if they were physically there. In this post-COVID environment, accessibility to the site allows Samsung Biologics to continue to sign contracts with existing and potential clients. Additionally, regulatory auditors can evaluate cGMP compliance and access the quality documentation system from any location around the world, ultimately creating a more efficient process by allowing them to conduct audits faster.